A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Nazartinib (Primary) ; Erlotinib; Gefitinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Sep 2019 Planned End Date changed from 31 May 2024 to 3 Jun 2024.
- 10 Sep 2019 Planned primary completion date changed from 12 Aug 2020 to 13 Aug 2020.
- 10 Sep 2019 Planned initiation date changed from 23 Jul 2018 to 24 Jul 2018.